Home Cart Sign in  
Chemical Structure| 21018-84-8 Chemical Structure| 21018-84-8

Structure of Amarogentin
CAS No.: 21018-84-8

Chemical Structure| 21018-84-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK.

Synonyms: AG

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Amarogentin

CAS No. :21018-84-8
Formula : C29H30O13
M.W : 586.54
SMILES Code : O=C(C1=C(O)C=C(O)C=C1C2=CC=CC(O)=C2)O[C@H]3[C@H](O[C@H]4[C@H](C=C)[C@@](CCO5)([H])C(C5=O)=CO4)O[C@H](CO)[C@@H](O)[C@@H]3O
Synonyms :
AG
MDL No. :MFCD06656289
InChI Key :DBOVHQOUSDWAPQ-WTONXPSSSA-N
Pubchem ID :115149

Safety of Amarogentin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Amarogentin

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HaCaT keratinocytes 100 μM 30 min Reduced histamine and TNF-α induced IL-8 and MMP-1 expression Mediators Inflamm. 2015;2015:630128
Splenocytes 0, 1, 10, 50 μM 24 h To evaluate the effect of AMA on PHA-induced IL-4 and IL-13 secretion in splenocytes, the results showed that AMA could reduce IL-4 and IL-13 production in a dose-dependent manner. Animal Model Exp Med. 2023 Jun;6(3):255-265
HaCaT cells 0, 1, 10, 50 μM 24 h To evaluate the effect of AMA on TNF-α-induced IL-6 secretion in HaCaT cells, the results showed that AMA could reduce IL-6 production in a dose-dependent manner. Animal Model Exp Med. 2023 Jun;6(3):255-265
HGC-27 cells 15, 30, 60 mM 24 h AG concentration-dependently inhibited HGC-27 cell proliferation, clone formation, and migration, and promoted apoptosis J Immunol Res. 2022 Jun 14;2022:2156204
LAD-2 cells 100 μM 30 min Inhibited SP-induced newly synthesized TNF-α production but did not affect histamine release Mediators Inflamm. 2015;2015:630128
Hepatic stellate cells 0.01, 0.1, 1 mg/mL 48 h To evaluate the effect of AG on TGF-β1-induced HSC proliferation, results showed AG significantly inhibited HSC proliferation and accelerated HSC apoptosis Molecules. 2017 May 6;22(5):754
Primary mouse cortical neuron cells 0.1-1 µM 72 h AMA significantly increased the neurite length in primary mouse cortical neuron cells, with 1 µM AMA treatment for 72 hours increasing neurite length from 41.7 ± 1.2 µm to 80.9 ± 5.7 µm. Biomedicines. 2021 May 20;9(5):581
PC12 cells 0.03-3 µM 48 h AMA induced neurite outgrowth in PC12 cells in a dose-dependent manner, with 3 µM AMA treatment for 48 hours resulting in 53.0% ± 2.1% of cells showing neurite outgrowth. Biomedicines. 2021 May 20;9(5):581
MG63 human osteoblasts 0–100 µg/ml Enhanced alkaline phosphatase activity and osteoblast proliferation Arch Med Sci. 2019 Nov 11;19(2):452-457

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice 2,4-dinitrochlorobenzene-induced AD-like mice model Topical application 1.0 mmol/L Once daily for 7 days To evaluate the therapeutic effect of AMA on AD-like mice, the results showed that AMA could promote the recovery of dermatitis, reduce the score of dermatitis severity and the scratching frequency, treat the skin lesions, reduce the epidermal thickness, decrease the infiltration of mast cells, reduce the IgE level in serum, decrease the expression levels of AD-related cytokines, increase protein and mRNA expression of FLG, and reduce the protein and mRNA expression of KLK7 in the skin tissues of AD-like mice. Animal Model Exp Med. 2023 Jun;6(3):255-265
C57BL/6 mice Carbon tetrachloride-induced liver fibrosis model Oral 25, 50, 100 mg/kg Once daily for six weeks To evaluate the protective effects of AG on carbon tetrachloride-induced liver fibrosis, results showed AG significantly improved liver function, reduced fibrosis markers, and exerted protective effects through anti-oxidative properties and suppression of the MAPK signaling pathway Molecules. 2017 May 6;22(5):754
Female Sprague Dawley rats Oestrogen-deficiency-induced osteoporosis rat model Oral 50 and 100 mg/kg 5 weeks Evaluated bone mineral density and serum biochemical markers, showing that Amarogentin significantly enhanced BMD and reduced inflammatory cytokine levels Arch Med Sci. 2019 Nov 11;19(2):452-457

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.70mL

0.34mL

0.17mL

8.52mL

1.70mL

0.85mL

17.05mL

3.41mL

1.70mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories